Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

American Academy of Neurology Fall Conference 2014
Brain MRI results of DECIDE: a randomized, double-blind trial of DAC HYP vs. IFNβ-1a in RRMS patients
Episode 40 with Dr. Raj Kapoor on a clinical trial of phenytoin
TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group.
A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing-remitting multiple sclerosis (TIME MS).
Differential effects of interferon-β1b on cytokine patterns of CD4+ and CD8+ T cells derived from RRMS and PPMS patients.
INF-β1b therapy modulates L-arginine and nitric oxide metabolism in patients with relapse remittent multiple sclerosis.
The complex role of estrogens in inflammation.
ACTRIMS-ECTRIMS 2014 -- Day 4
Development of oral immunomodulatory agents in the management of multiple sclerosis.
A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis.
High-Dose Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation for Relapsing-Remitting Multiple Sclerosis (HALT-MS): A 3-Year Interim Report.
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.
Suppression of CD4+ T cell activation by a novel inhibitor of Src family kinases.
A timing-of-birth effect on multiple sclerosis clinical phenotype.
Glatiramer promotes oligodendroglial cell maturation in a cuprizone-induced demyelination model.
Spontaneous relapsing-remitting EAE in the SJL/J mouse: MOG-reactive transgenic T cells recruit endogenous MOG-specific B cells.
Defining the clinical course of multiple sclerosis: The 2013 revisions.
Estriol preserves synaptic transmission in the hippocampus during autoimmune demyelinating disease.
Structure of the LINGO-1-anti-LINGO-1 Li81 antibody complex provides insights into the biology of LINGO-1 and the mechanism of action of the antibody therapy.
Risk alleles for multiple sclerosis identified by a genomewide study.
Phase III study: Ocrelizumab significantly reduces disease activity in PPMS patients
20th Annual Rehabilitation In Multiple Sclerosis (RIMS) Conference
IFN-β Treatment Requires B Cells for Efficacy in Neuroautoimmunity.
Episode 36 with Dr. Jenny Ting on the inflammasome

Pages